Cary, NC, Jan. 10, 2025 (GLOBE NEWSWIRE) -- INE, a global leader in networking and cybersecurity training and certifications, is proud to announce it is the recipient of 14 badges in G2’s Winter 2024 Report, including “Enterprise Leader, Online Course …
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as susceptible to PEMGARDA) together constitute the majority …
Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net Revenue of $211 Million, 10% in Constant Currency Beverage Revenue Increase …
Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its Searchlight™ chemoproteomics platform SAN MATEO, Calif. and SAN …
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to …
Precision Medicine Market Industry Outlook 2025 By Ecosystem Players, By Sub-Markets, By Therapeutics, And By Region Forecast 2032 EU, EUROPEAN UNION, SPAIN, January 10, 2025 /EINPresswire.com/ -- Precision Medicine Market Overview Precision medicine …
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will combine vepdegestrant with a CDK4/6 inhibitor, also …
The Global Botox Market Industry has witnessed a significant rise in demand for aesthetic procedures, particularly among the aging population. NEW YORK, NY, UNITED STATES, January 10, 2025 /EINPresswire.com/ -- 𝚆𝙶𝚁 released the report titled "Botox …
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8 Primary endpoint met in phase 2a POC trial in bipolar II disorder with …
Birch Company is poised for substantial growth in 2025 amidst favorable US housing market ATWEC Technologies, Inc (OTCMKTS:ATWT) TULSA, OK, UNITED STATES, January 10, 2025 /EINPresswire.com/ -- Birch Company (OTC: ‘ATWT’), the operating subsidiary of …
French Optical offers fast and efficient same-day eyeglass repairs in NYC, ensuring busy New Yorkers get their glasses fixed without delay. NEW YORK, NY, UNITED STATES, January 10, 2025 /EINPresswire.com/ -- Residents of New York City now have a …
Helping senior living operators reduce food costs, streamline operations, and enhance ROI with integrated menu planning and inventory tools LOUISVILLE, KY, UNITED STATES, January 10, 2025 /EINPresswire.com/ -- Aline™, the leading provider of senior …
PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. “We are pleased to …
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in …
PopUp Bagels, the "Not famous but known" bagel shop, famous for introducing the “Grip, Rip and Dip’ food craze, has officially announced the opening of its newest location in Boston. BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PopUp Bagels, the …
ENGLEWOOD CLIFFS, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today announced that it plans to release results for the fourth quarter ended …
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical …
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD- …
ORLANDO, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company”) (NYSE American: GENC) announced that on January 3, 2025 it received a filing delinquency notification (the “Delinquency Notification”) from the NYSE Regulation (the “ …
Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney Disease Plans to Initiate Rare Kidney Diseases Cohort in Early 2025 Company to Attend 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE …
01 days 16:54:03
